Shingles protection for adults with immunocompromise

+Practice

In print

Vaccines

Shingles protection for adults with immunocompromise

25 September 2024

Mary Nowlan

Wednesday 25 September 2024, 12:20 AM

This article details the recent widening of eligibility for funded herpes zoster vaccine to immunocompromised adults

Key points, Herpes zoster is a painful and potentially severe condition. Highest incidence of zoster is seen in those with immunocompromise and/or older age. , Pract Green w Pale Yellow

Infectious Disease

References

Bhavsar A, Lonnet G, Wang C, et al. Increased risk of herpes zoster in adults ≥50 years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis 2022;9(5):ofac118.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. NEJM 2016;375(11):1019–32.
Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barre syndrome following recombinant zoster vaccine in Medicare beneficiaries. JAMA Intern Med 2021;181(12):1623–30.
Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (Shingrix): Real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis 2021;73(6):941–48.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. NEJM 2015;372(22):2087–96.
Marijam A, Vroom N, Bhavsar A, et al. Systematic literature review on the incidence of herpes zoster in populations at increased risk of disease in the EU/EEA, Switzerland, and the UK. Infect Dis Ther 2024;13(5):1083–104.
Oostvogels L, Heineman TC, Johnson RW, et al. Medical conditions at enrolment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vacc Immunother 2019;15(12):2865–72.
Racine E, Gilca V, Amini R, et al. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49-year-old patients. Vaccine 2020;38(40):6205–14.
Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis 2022;9(10):ofac485.
Tavares-Da-Silva F, Co MM, Dessart C, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine 2020;38(18):3489–500.
Walia A, Sun Y, Acharya NR. Risk of herpes zoster ophthalmicus recurrence after recombinant zoster vaccination. JAMA Ophthalmol 2024;142(3):249–56.

How to Treat

Prostate cancer consultations are common in primary care and there is no one approach to testing and treatment that fits all patients. Urologist Simon van Rij discusses the key considerations and options for personalised care, appropriate investigation and treatment

Wednesday 11 September 2024, 12:45 AM